Myeloma Drug Pulled From Market Just Months After Approval

(MedPage Today) -- Just months after FDA granted accelerated approval of its myeloma drug, Oncopeptides has pulled melphalan flufenamide (melflufen, Pepaxto) from the market.
The decision followed an FDA hold on clinical trials of the drug after...